The successful use of Cantrixil in combination with cisplatin for the treatment of Primary Ovarian Cancer has recently been reported in full. It was first reported last year that “Intraperitoneal administration of Cantrixil at a dose of 100 mg/kg as a first-line therapy in combination with standard of care (cisplatinum or paclitaxel), improved survival compared with the respective monotherapy controls (p<0.001)”
What is really important about the content of that paragraph is it is talking about an expanded use of Cantrixil. Previous analyst reports have calculated the potential revenue from Cantrixil based on it being used in patients with advanced cancer and malignant ascities. Clearly, using it as part of the treatment regimen for first line treatment of Primary Ovarian Cancer greatly expands how the potential revenue will be calculated. http://www.novogen.com/pdf/October2015Edison_Report_Sharper_Focus_On_Anti-Cancer_Drugs.pdf
NRT Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
